Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Depreciation & Amortization (CF): 2016-2024

Historic Depreciation & Amortization (CF) for Dianthus Therapeutics (DNTH) over the last 9 years, with Dec 2024 value amounting to $96,000.

  • Dianthus Therapeutics' Depreciation & Amortization (CF) rose 8.00% to $27,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $110,000, marking a year-over-year increase of 22.22%. This contributed to the annual value of $96,000 for FY2024, which is 43.28% up from last year.
  • According to the latest figures from FY2024, Dianthus Therapeutics' Depreciation & Amortization (CF) is $96,000, which was up 43.28% from $67,000 recorded in FY2023.
  • Over the past 5 years, Dianthus Therapeutics' Depreciation & Amortization (CF) peaked at $2.0 million during FY2021, and registered a low of $67,000 during FY2023.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $96,000 (2024), whereas its average is $696,000.
  • Per our database at Business Quant, Dianthus Therapeutics' Depreciation & Amortization (CF) slumped by 96.52% in 2023 and then surged by 43.28% in 2024.
  • Over the past 5 years, Dianthus Therapeutics' Depreciation & Amortization (CF) (Yearly) stood at $2.0 million in 2020, then climbed by 1.00% to $2.0 million in 2021, then fell by 4.70% to $1.9 million in 2022, then tumbled by 96.52% to $67,000 in 2023, then skyrocketed by 43.28% to $96,000 in 2024.